Fibromyalgia is classified as a chronic primary pain condition. In the World Health Organization’s current diagnostic system (ICD-11), it falls under code MG30.0, which defines chronic primary pain as pain characterized by emotional distress or functional disability that is not better explained by another underlying condition. This means fibromyalgia is recognized as a health condition in its own right, not merely a symptom of something else.
That classification didn’t come easily. For decades, fibromyalgia sat in a gray zone between rheumatology, neurology, and psychiatry, with no clear medical home. Understanding how it’s classified today, and why that classification changed, helps explain both the condition itself and why getting a diagnosis still takes an average of 2 to 3.5 years.
A Pain Condition, Not a Musculoskeletal Disease
One common point of confusion is whether fibromyalgia is a type of arthritis or autoimmune disease. It is neither. While rheumatologists often diagnose it, and it frequently coexists with inflammatory conditions, fibromyalgia does not involve joint inflammation or immune system attacks on tissue. Its placement under chronic primary pain reflects this distinction: the pain itself is the condition, not a byproduct of damage happening elsewhere in the body.
The International Association for the Study of Pain has introduced a more specific term for the type of pain fibromyalgia produces: nociplastic pain. This describes pain that arises from changes in how the nervous system processes pain signals, even though there is no clear tissue damage or nerve injury causing it. In practical terms, the brain and spinal cord amplify pain signals, so sensations that wouldn’t normally hurt, or would only hurt mildly, become intense and persistent. This is distinct from the pain you feel from a broken bone (where tissue is damaged) or from a pinched nerve (where the nerve itself is injured). People with fibromyalgia can have normal-looking scans and bloodwork while experiencing very real, measurable pain.
How Diagnostic Criteria Have Evolved
The way doctors identify fibromyalgia has changed significantly over three decades, and each revision reflects a shift in how the condition is understood.
The original 1990 criteria from the American College of Rheumatology required two things: widespread pain in all four quadrants of the body plus the spine, and at least 11 out of 18 specific tender points that hurt when pressed by a physician. This approach had a major practical problem. Tender point exams were inconsistent. Different doctors applied different amounts of pressure, and a patient’s tenderness could vary from day to day. Many people with clear fibromyalgia symptoms failed the tender point test, while some without the condition passed it.
In 2010, the criteria were overhauled. Tender points were dropped entirely. Instead, doctors began using two scales: a Widespread Pain Index (WPI) that counts how many of 19 body regions are painful, and a Symptom Severity Scale (SSS) that rates the severity of fatigue, unrefreshing sleep, and cognitive difficulties. A 2011 modification went further, allowing the diagnosis to be made entirely through patient self-report rather than requiring a physical exam.
The most current version, revised in 2016, requires all of the following: pain in at least 4 of 5 body regions, symptoms present at a similar level for at least 3 months, and either a WPI of 7 or higher with an SSS of 5 or higher, or a WPI of 4 to 6 with an SSS of 9 or higher. Importantly, the 2016 criteria also established that a fibromyalgia diagnosis is valid regardless of other diagnoses. Having lupus or rheumatoid arthritis, for example, does not rule out a simultaneous fibromyalgia diagnosis.
Why It Takes So Long to Diagnose
Despite clearer criteria, the average time from symptom onset to a fibromyalgia diagnosis is about 3.5 years. Research across multiple countries has found that patients often see three or more physicians before receiving a definitive answer, consulting an average of 3.7 doctors along the way. Part of this delay comes from the nature of the condition: there is no blood test, imaging scan, or biopsy that confirms fibromyalgia. It is diagnosed based on symptom patterns after other conditions have been considered.
That diagnostic delay matters. Studies show that longer delays are associated with worse outcomes and greater symptom severity by the time patients finally receive their diagnosis and begin appropriate treatment.
Conditions That Look Similar
Because fibromyalgia is diagnosed by its symptoms rather than a definitive test, distinguishing it from overlapping conditions is a real clinical challenge. Small fiber neuropathy is one of the closest mimics. Both cause widespread pain, and both can exist alongside anxiety and depression.
Some features help point in one direction. Stabbing pain, tingling, changes in sweating patterns, skin color changes, and reduced hair or nail growth on the lower legs are more suggestive of small fiber neuropathy. That condition also tends to follow a length-dependent pattern, starting in the feet and hands. Fibromyalgia, on the other hand, is more commonly associated with headaches, jaw pain, and a history of post-traumatic stress or physical abuse. When clinical signs alone aren’t enough, skin biopsies and specialized nerve testing can help separate the two.
Fibromyalgia also commonly coexists with inflammatory rheumatic diseases and musculoskeletal disorders, while small fiber neuropathy is more often linked to metabolic conditions like diabetes, toxic exposures, and certain autoimmune diseases like Sjögren’s syndrome.
Who Gets Fibromyalgia
Fibromyalgia affects an estimated 1 to 5 percent of the global population. It is diagnosed far more often in women: in large clinical studies, roughly 87 percent of diagnosed patients are female. Whether this reflects a true biological difference in susceptibility, differences in how men and women report pain, or diagnostic bias remains an open question. The 2016 criteria, by relying on standardized symptom scales rather than subjective physical exams, were designed in part to reduce this kind of variability.
What the Classification Means for Patients
How a condition is classified might sound like a bureaucratic detail, but it has real consequences. Fibromyalgia’s recognition as a chronic primary pain condition in ICD-11 means it has a formal diagnostic code that insurance systems, disability evaluations, and healthcare providers worldwide can reference. It validates the condition as something that exists independently, not as a diagnosis of exclusion or a catch-all label for unexplained symptoms.
The nociplastic pain framework adds another layer. By identifying the mechanism as altered pain processing rather than tissue damage, it points treatment toward approaches that target the nervous system: medications that calm pain signaling, exercise programs that gradually retrain the body’s response, and cognitive behavioral strategies that address the brain’s role in pain amplification. This is fundamentally different from treatments aimed at reducing inflammation or repairing tissue, which is why anti-inflammatory drugs like ibuprofen typically offer little relief for fibromyalgia on their own.